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Cardiotoxicity is a well-known and potentially serious 
complication of antitumor treatment. The greatest risk for 
development of carditoxicity represent anthracyclines [1] 
and high-dose chemotherapy �HD-CT�� especially regi-
mens containing high-dose cyclophosphamide [��5].
Myeloa�lative preparative regimen �PR�� in acute 
leukemia �AL�� contains high-dose cyclophosphamide 
in total dose of 1�� mg/kg �HD-C���� in some cases in 
com�ination with fractionated total �ody irradiation �TBI�� 
1� Gy. This is followed �y hematopoietic cell transplanta-
tion �HCT��. Moreover�� these patients are pretreated with 
conventional chemotherapy �CT�� containing anthracy-
clines in a relatively high cumulative dose �CD��. All of 
these therapeutic procedures are potentially cardiotoxic 
and require thorough monitoring of cardiac functions 
during the treatment �acute cardiotoxicity�� and after its 
completion �chronic and late cardiotoxicity��.
Various methods have �een recommended for 
monitoring of cardiotoxicity [6�8]. In our conditions�� 
echocardiography and electrocardiography are rou-
tinely used. Recently�� �iochemical markers of cardiac 
damage�� especially natriuretic peptides and cardiac 
troponins�� are gaining ground in this field [�].
Natriuretic peptides � atrial natriuretic peptide �ANP���� 
�rain natriuretic peptide �BNP�� and N-terminal pro �rain 
natriuretic peptide �NT-proBNP�� — are produced �y 
myocardium in response to wall strain and pressure 
overload [1�]. ANP is produced mainly in atria�� BNP/
NT-proBNP predominantly in ventricles. In cardiology�� 
natriuretic peptides are routinely used in diagnostics 
of heart failure [11]. Normal plasma BNP/NT-proBNP 
concentrations practically exclude heart failure due to 
high negative predictive value of the test [1�].
Cardiac troponins — cardiac troponin T �cTnT���� car-
diac troponin I �cTnI�� — and myocardial izoenzyme of 
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Introduction: Cardiotoxicity is a relatively frequent and potentially serious complication of antitumor treatment. Anthracyclines and other 
high-dose chemotherapy represent the greatest risk. The aim of the study was to assess cardiotoxicity during preparative regimen (PR) and 
hematopoietic cell transplantation (HCT) in acute leukemia (AL) with biochemical markers — “N-terminal pro brain natriuretic peptide” 
(NT-proBNP), cardiac troponin T (cTnT) and creatine kinase MB (CK-MB mass). Methods: Nineteen adult AL patients previously 
treated with anthracyclines — idarubicine, daunorubicine, mitoxantrone with standard doses for a cycle as 3 х 12 mg/m2, 3 х 50 mg/m2, 
3 х 10 mg/m2 accordingly were studied. PR consisted of high-dose cyclophosphamide (HD-C) in combination with busulphan or total 
body irradiation (TBI). Plasma NT-proBNP, cTnT and CK-MB mass concentrations were measured the day before PR, the day after 
PR, the day after HCT and 14 days after HCT. Results: Before PR, mean plasma NT-proBNP value was 106.3 ± 55.7 ng/l. After PR, it 
increased to 426.1 ± 391.5 ng/l. After HCT, a further increase to 847.6 ± 780.6 ng/l was observed. Fourteen days after HCT, the mean 
NT-proBNP was 330.8±236.8 ng/l. The differences were statistically significant in comparison with the baseline values (p < 0.01). The 
NT-proBNP elevations were more pronounced in patients with cumulative doses (CD) of anthracyclines above 450 mg/m2 (p < 0.05), in 
patients with PR containing HD-C and TBI (p < 0.05). In all patients, plasma cTnT and CK-MB mass concentrations remained unchang-
able during PR and HCT. Conclusion: Our results suggest that administration of PR and HCT is in most AL patients associated with acute 
neurohumoral activation (significant rise in NT-proBNP). Persistent NT-proBNP elevations, in our study in 12 (63.2 %) patients, indicate 
subclinical cardiotoxicity (risk for development of heart failure) and require further follow-up. More pronounced NT-proBNP elevations in 
patients with higher CD of anthracyclines and in patients with PR containing combination of HD-C and TBI confirm that these therapeutic 
procedures seem to be more cardiotoxic and not very appropriate for patients with cumulation of risk factors for cardiotoxicity. Negative 
plasma cTnT and CK-MB mass concentrations show no detectable damage of cardiomyocyte structure during PR and HCT.
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creatine kinase �CK-MB�� are cardiospecific markers that 
show structural damage of cardiomyocytes from various 
causes�� including cardiotoxic effect of CT [1�]. 
Assessment of cardiotoxicity of HD-CT with �io-
chemical markers of structural or functional myocardial 
damage was the aim of only a few studies from recent 
time. In some studies�� cardiac troponins [1��16] and 
natriuretic peptides [1��1�] were suggested as predic-
tors of late cardiac dysfunction after HD-CT and HCT. 
In these studies�� different types of HD-CT were used in 
various�� not only hematological malignancies. Accord-
ing to availa�le literature�� monitoring and comparison 
of acute cardiotoxicity of PR used in AL was not the 
su�ject of any study so far.
The aim of the presented study was to assess 
cardiotoxicity during PR and HCT in AL with �iochemi-
cal markers � NT-proBNP�� cTnT�� CK-MB mass — and 
echocardiography �ECHO��. We compared cardiotoxici-
ty of two myeloa�lative PR used in AL. We assessed 
the impact of prior anthracycline treatment on plasma 
concentrations of �iochemical markers of cardiac 
damage in the peritransplant period.
METHODS
Patients. Nineteen consecutive adult patients with 
AL were studied. The patients consisted of 1� males and 
6 females with the mean age of ��.8 ± 1�.� years �range: 
���56��. Four of the patients were treated for arterial hy-
pertension�� the other patients had no known pre-existing 
cardiovascular disease. Renal and liver functions were nor-
mal in all patients. The patients were treated with conven-
tional CT containing anthracyclines in total CD of ��6.� ± 
�1.6 mg/m� �range: ����6����. To calculate the total CD 
of anthracyclines�� we applied conversion factors derived 
from the maximum recommended cumulative doses for 
individual agents used �idaru�icine�� daunoru�icine and 
mitoxantrone��. The standard doses for a cycle of chemo-
therapy were: idaru�icine � x 1� mg/m��� daunoru�icine � x 
5� mg/m��� mitoxantrone � x 1� mg/m�. In all patients�� PR 
consisted of intravenous Cyclophosphamide in total dose 
of 1�� mg/kg �HD-C���� in 1� patients in com�ination with 
peroral Busulphan 16 mg/kg �Bu/HD-C�� and in 6 patients 
in com�ination with fractionated total �ody irradiation 
1� Gy �TBI/HD-C��. In all cases�� cryopreserved peripheral 
�lood stem cells were used as the source for HCT. Ten 
patients were given allogeneic grafts and � autologous 
grafts. The study was approved �y the local ethical com-
mittee. All patients gave a written consent �efore they were 
included in the study.
Biochemistry. �erial measurements of plasma 
NT-proBNP�� cTnT and CK-MB mass concentrations 
were performed the day �efore PR�� the day after PR�� 
the day after HCT and 1� days after HCT�� i. e. at the 
time of �one marrow recovery.
Venous �lood samples were o�tained from an indwell-
ing catheter after �� min of rest in supine position. The 
�lood samples were withdrawn into chilled tu�es contain-
ing EDTA. The whole �lood was immediately centrifuged�� 
the plasma was decanted�� frozen and stored at ��� °C until 
assayed. Plasma concentrations of �iochemical markers 
were measured �y electrochemiluminescence immuno-
assay on Elecsys 1�1� analyzer �Roche Diagnostics��. 
Based on a num�er of studies�� NT-proBNP values 
�ellow 1�� ng/l for male�� 15� ng/l for female are con-
sidered normal and allow to rule out heart failure due 
to high negative predictive value of the test [1��� ��]. 
We used these cut-off values for cardiac dysfunction. 
Values a�ove cut-off respecting gender �1�� ng/l for 
male�� 15� ng/l for female�� were considered elevated�� 
NT-proBNP concentrations a�ove 5�� ng/l were conside-
red markedly elevated. Elevated NT-proBNP concentra-
tions in association with the given treatment show func-
tional myocardial damage and are a sign of toxic effect 
of the treatment on myocardium. CTnT concentrations 
a�ove �.�1 µg/l and CK-MB mass concentrations a�ove 
�.�� µg/l were taken as elevated and showing structural 
damage of cardiomyocytes caused �y the treatment. 
Echocardiography. ECHO was performed �efore PR 
and in the early period after HCT �within � days after HCT��. 
The ECHO evaluation was done with Hewlett Packard Im-
age Point ultrasound �y an experienced echocardiogra-
phist. Parameters of systolic and diastolic left ventricular 
�LV�� function and presence of pericardial effusion were as-
sessed. In the study�� systolic LV dysfunction was defined as 
ejection fraction �EF�� �ellow 55%. Diastolic LV dysfunction 
was defined as E/A inversion and deceleration time �DT�� 
a�ove ��� ms on the transmitral Doppler curve �impaired 
relaxation��. Pericardial effusion was defined as separation 
of pericardial leaves at least � mm in systole.
Statistical analysis was performed with the “�ta-
tistica for Windows�� Version 5.�” program. Analysis 
of variance �ANOVA���� paired two tailed t-tests and 
McNemar tests were used. Correlations were evaluated 
with normal and �pearman correlation tests. The values 
are expressed as mean ± �D. Pro�a�ility values < �.�1 
and < �.�5 were considered statistically significant. 
RESULTS AND DISCUSSION
�ignificance of NT-proBNP for evaluation of cardio-
toxicity. The day �efore PR�� mean plasma NT-proBNP 
concentration was 1�6.� ± 55.� ng/l �slightly elevated 
in � patients��. The mean NT-proBNP concentration in-
creased to ��6.1 ± ��1.5 ng/l �elevated in 1� patients�� 
markedly elevated in 5 patients�� after completion of 
PR. After HCT�� a further increase to 8��.6 ± �8�.6 ng/l 
�elevated in 1� patients�� markedly elevated in � patients�� 
was o�served. At the time of �one marrow recovery 
�1� days after HCT���� the mean NT-proBNP concentra-
tion was ���.8 ± ��6.8 ng/l. Values remained elevated 
in 1� �6�.�%�� patients�� markedly elevated in 5 ��6.� %�� 
patients. The differences were statistically significant 
in comparison with the �aseline NT-proBNP value �p < 
�.�1�� Fig. 1��. The NT-proBNP elevations were more 
pronounced in patients with CD of anthracyclines a�ove 
�5� mg/m� �p < �.�5���� in patients with PR containing 
TBI and HD-C �p < �.�5�� Fig. � and ���. The changes in 
NT-proBNP concentrations were not significantly dif-
ferent after infusion of allogeneic or autologous grafts. 
Associations �etween changes in NT-proBNP concentra-
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tions and gender�� age or history of arterial hypertension 
were not significant. 
Fig. 1. Plasma NT-proBNP concentrations in the peritransplant 
period in AL patients. *p < �.�1 vs �efore PR.
Fig. 2. Plasma NT-proBNP concentrations in the peritransplant 
period according to CD of anthracyclines. �p < �.�5��
Fig. 3. Plasma NT-proBNP concentrations in the peritransplant 
period according to PR. �p < �.�5��
Explanatory notes to Fig. 1��: �efore PR — the day �efore initia-
tion of preparative regimen�� after PR — the day after completion 
of preparative regimen�� after HCT — the day after hematopoietic 
cell transplantation �graft infusion���� day + 1� — 1� days after 
hematopoietic cell transplantation ��one marrow recovery��. 
�lightly elevated NT-proBNP concentrations �efore 
PR were in � ��1.1%�� patients. These elevations were likely 
caused �y prior anthracycline-�ased CT. More pronounced 
NT-proBNP elevations in patients with higher CD of anthra-
cyclines and in patients with PR containing com�ination of 
HD-CT and radiotherapy suggest that these therapeutic 
procedures are associated with higher myocardial strain�� 
and thus seem to �e more cardiotoxic. In our previously 
pu�lished study�� we proved that solely intravenous hydra-
tion in AL patients does not lead to significant increase in 
NT-proBNP concentrations [�1]. In the study of �nowden 
et al.�� administration of PR containing HD-C was associated 
with higher NT-proBNP elevation than other PR [1�]. �o far�� 
there are no other studies comparing acute cardiotoxicity 
of different PR �y means of natriuretic peptides.
Three studies from recent time have dealt with the 
assessment of cardiotoxicity of HD-CT and HCT [1��1�]. 
In these studies�� most patients had significant elevations 
in BNP/NT-proBNP after HD-CT and HCT. Persistent NT-
proBNP elevations were o�served in �����% patients. 
During follow-up�� the patients with persistent BNP/
NT-proBNP elevations had more often cardiac dysfunction 
than the other patients. The results show that monitoring 
of BNP/NT-proBNP could identify patients at risk for deve-
lopment of cardiac dysfunction after HD-CT and HCT.
In our patients�� elevated NT-proBNP concentrations 
1� days after HCT were found in a higher percentage of 
patients than in the study of Niwa et al — 6�.�% versus 
�5.6% [18]. This difference could �e explained �y rela-
tively high CD of anthracyclines in our patients — even 
�efore PR �1.1% patients had a slightly elevated 
NT-proBNP. The results can �e influenced �y the num-
�er of patients took that part in the study.
In the peritransplant period�� one �5.�%�� of the 
patients developed manifestation of cardiotoxicity — 
clinical signs of heart failure�� mild systolic dysfunc-
tion �EF 5�%���� NT-proBNP concentrations 65�.� ng/l 
�after PR�� and ���8.� ng/l �after HCT��. In this patient�� 
�aseline NT-proBNP was �1�.� ng/l�� which was �y far 
the highest value in the group. This patient had CD of 
anthracyclines a�ove the maximum recommended CD 
�55� mg/m����� PR contained com�ination of TBI and 
HD-C and allogeneic HCT was performed.
Cardiospecific markers �cTnT and CK-MB mass��. There 
were no differences in plasma level of cTnT and CK-MB mass 
during the PR and HCT�� which earlier considered as showing 
no detecta�le damage of cardiomyocyte structure �Ta�le 1��. 
However�� cTnT is pro�a�ly not the most sensitive marker for 
cardiac damage caused �y oncology treatment.
Table 1. Plasma concentrations of cardiospecific markers in the peritrans-
plant period in AL patients
Cardiospecific markers Before PR After PR After HCT Day +14 p
cTnT [µg/l] < 0.01 < 0.01 < 0.01 < 0.01 NS
CK-MB mass [µg/l] 1.094 ± 
0.511
1.218 ± 
0.418
1.183 ± 
0.346
1.117 ± 
0.472
NS
Measurement of cardiac troponins is a very sensitive 
method that is a�le to detect a minimal damage of cardio-
myocytes after HD-CT [15�� ��]. In the recently pu�lished 
study �y Cardinale et al.�� cTnI positivity �≥ �.�8 µg/l�� 
within �� h after HD-CT was seen in nearly ��% of on-
cology patients. CTnI positivity was associated with a 
significantly higher decrease in LV EF and other cardiac 
events during �-year follow-up [16].
Assessment of cTnT and cTnI is for clinical use 
equivalent. However�� only assessment of cTnT is stan-
dardized at present [��]. According to the results of 
Cardinale et al.�� we would expect at least low positivity of 
cTnT in a�out 5 patients. Despite using a highly sensitive 
assay on cTnT with sensitivity of �.�1 µg/l�� we did not find 
cTnT positivity in any of our  patients after PR and HCT. 
This finding is in concordance with the study of Auner 
et al.�� in which administration of HD-C and TBI 1� Gy did 
not lead to elevation of cTnT in any of �� hematooncolo-
gy patients [��]. Either in the study of Benvenuto et al.�� 
administration of HD-C caused no elevation in cTnI [�5]. 
At present�� routine use of cardiac troponins for monitor-
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ing of cardiotoxicity of antitumorous treatment cannot 
�e esta�lished to clinical practice due to disunity of the 
availa�le assays �lack of standardization�� and inconsis-
tence of results. The timing of sample collection and 
determination of cut-off value for treatment-related 
cardiotoxicity may play an important role.
Echocardiography. Changes in ECHO parameters 
during the peritransplant period are shown in Ta�le �. 
Correlations �etween plasma NT-proBNP concentra-
tions and ECHO parameters did not reach statistical sig-
nificance.In the early period after PR and HCT�� we found 
a decrease in systolic LV function �LV EF 6�.� ± 1.�% 
vs 61.� ± �.5%���� which was statistically significant �p < 
�.�5��. In 1 �5.�%�� of the patients�� a decrease in LV EF 
function more than 1�% with symptoms of heart failure 
developed. In the other patients�� LV EF remained within 
normal range �a�ove 55%��. After PR and HCT�� diastolic 
LV dysfunction newly appeared in � patients and small 
pericardial effusion in � patients. These changes in 
ECHO parameters are caused �y com�ination of acute 
impact of PR and HCT and influence of the prior anthra-
cycline treatment. Newly developed pericardial effusion 
after PR and HCT in � �1�.5%�� patients and presence 
of pericardial effusion altogether in 6 ��1.6%�� is lower 
than pu�lished in the literature. After PR containing 
HD-C�� pericardial effusion has �een reported in up to 
�� % of patients [�6].
Table 2. Abnormal ECHO findings in the peritransplant period in AL patients
Abnormal ECHO findings Before PR and HCT After PR and HCT p
Systolic LV dysfunction  0 1 (5.3%) NS
Diastolic LV dysfunction 3 (15.8%) 6 (31.6%) NS
Pericardial effusion 4 (21.1%) 6 (31.6%) NS
We are aware that our results are partially limited �y 
the num�er of patients participating in the study and a 
relatively short period of the follow-up. These findings 
require a further prospective follow-up and confirming in 
further studies in a larger num�er of patients. Long-term 
cardiology follow-up is warranted in all oncology patients 
treated with anthracyclines and HD-CT followed �y HCT. 
Our results show that administration of PR and HCT 
is in most AL patients associated with acute neurohu-
moral activation �significant rise in NT-proBNP��. In our 
study�� NT-proBNP remained elevated in 1� �6�.�%�� 
patients at the time of �one marrow recovery. These 
persistent NT-proBNP elevations indicate su�clinical 
cardiotoxicity �risk for development of heart failure�� and 
require further follow-up. NT-proBNP elevations were 
significantly more pronounced in patients with higher 
CD of anthracyclines and in patients with PR containing 
com�ination of radiotherapy and HD-CT. Thus�� these 
therapeutic procedures seem to �e more cardiotoxic 
and not very appropriate for patients with cumulation of 
risk factors for cardiotoxicity. Predictive value of these 
changes is not clear and must �e yet determined.
Administration of PR and HCT may lead to manifes-
tation of cardiotoxicity — in our study in 1 �5.�%�� of the 
patients. Development of acute heart failure in the patient 
with the highest �aseline NT-proBNP concentration sug-
gests that implementation of NT-proBNP to commonly 
performed pretransplant cardiac examinations could 
�e useful in the identification of patients at high risk for 
development of cardiotoxicity in terms of heart failure and 
in the early diagnostics of cardiac dysfunction in the peri-
transplant period. Relatively high price of this assay and 
necessity of repeated measurements remains the limita-
tion for implementation to routine clinical practice.
In our study�� negative plasma cTnT and CK-MB mass 
concentration show no detecta�le damage of cardio-
myocyte structure during PR and HCT. Thus�� routine 
measurement of these cardiospecific markers in the 
peritransplant period in asymptomatic patients does not 
seem to �e of value in the detection of cardiotoxicity. 
However�� further studies using more sensitive markers 
of cardiac damage �such as ischemia modified al�umin�� 
fatty acid �inding protein�� glycogen phosphorylase BB�� 
could �ring a new view on this issue.
Cardiotoxicity of oncology treatment develops 
mainly in the com�ination of more potentially cardiotoxic 
procedures�� as in case of AL treatment. Cardiotoxicity 
is a serious interdisciplinary pro�lem that requires co-
operation of an oncologist with a cardiologist. 
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БИОХИМИЧЕСКИЕ МАРКЕРЫ И ОЦЕНКА КАРДИОТОКСИЧНОСТИ 
В ТЕЧЕНИЕ ПРЕДВАРИТЕЛЬНОЙ ТЕРАПИИ ПАЦИЕНТОВ 
С ОСТРЫМ ЛЕЙКОЗОМ С ПОСЛЕДУЮЩЕЙ ТРАНСПЛАНТАЦИЕЙ 
СТВОЛОВЫХ ГЕМАТОПОЭТИЧЕСКИХ КЛЕТОК
Введение: кардиотоксические осложнения — это относительно частые и потенциально опасные последствия противоопухолевой 
терапии. Наибольшую кардиотоксичность отмечают при применении высоких доз химиопрепаратов, в частности антибиотиков 
антрациклинового ряда. Целью данного исследования была оценка кардиотоксичности при лекарственной подготовке пациентов 
с острым лейкозом (ОЛ) и проведении им трансплантации гематопоэтических стволовых клеток (ГСК), а также определение 
следующих биохимических маркеров – N-терминального промозгового натрийуретического пептида (NT-proBNP), сердечного 
тропонина T (cTnT) и креатинкиназы MB (CK-MB). Методы: обследованы 19 взрослых пациентов с ОЛ, прошедших предварительное 
лечение (ПЛ) с применением антрациклиновых антибиотиков (АА) – идарубицина, даунорубицина, митотриксантрона в дозах 3 
х 12 мг/м2, 3 х 50 мг/м2, 3 х 10 мг/м2 соответственно. Кроме применения АА, ПЛ включало высокие дозы циклофосфамида 
(ВД-Ц) в сочетании с бусульфаном или радиолучевой терапией (РЛТ). Концентрацию NT-proBNP, cTnT и CK-MB определяли 
в плазме крови за день до и через день после проведения ПЛ, а также за день до и через 14 дней после трансплантации ГСК. 
Результаты: уровень NT-proBNP перед проведением ПЛ составил 106,3 ± 55,7 нг/л, а после повышался до 426,1 ± 391,5 нг/л. 
После трансплантации ГСК отмечали дальнейшее возрастание исследуемого показателя до 847,6 ± 780,6 нг/л. Через 14 дней 
после трансплантации ГСК концентрация NT-proBNP достигла 330,8 ± 236,8 нг/л, при этом разница была статистически 
достоверна по сравнению с исходными значениями (p < 0,01). Повышение уровня NT-proBNP в плазме крови более выражено 
у пациентов, получавших АА в суммарной дозе (СД) выше 450 мг/м2 (p < 0,05), а также у больных, получавших ВД-Ц и РЛТ (p 
< 0,05). Концентрация cTnT и CK-MB при проведении ПЛ и трансплантации ГСК не изменялась по отношению к исходному 
уровню. Выводы: показано, что применение ПЛ и трансплантация ГСК у большинства пациентов с ОЛ сопровождается острой 
нейрогуморальной активацией, что проявлялось в существенном повышении уровня NT-proBNP. Постоянно высокий уровень NT-
proBNP, отмеченный у 12 (63,2%) пациентов, свидетельствует о бессимптомной кардиотоксичности (риске развития сердечной 
недостаточности) и требует последующего врачебного наблюдения больных. Более выраженное повышение уровня NT-proBNP 
у пациентов с более высокой СД АА и у больных, получавших ВД-Ц и РЛТ, свидетельствует о том, что такое лечение является 
более кардиотоксичным и не рекомендовано для применения в случае наличия факторов риска проявления кардиотоксичности.
Ключевые слова: кардиотоксичность, биохимические маркеры, трансплантация, острый лейкоз.
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